Pharmacyclics Llc.
Clinical trials sponsored by Pharmacyclics Llc., explained in plain language.
-
New combo therapy shows promise for common blood cancer
Disease control CompletedThis study tested whether adding the drug ibrutinib to standard rituximab therapy helps people with untreated follicular lymphoma live longer without their cancer getting worse. About 445 patients aged 60 or older (or 60-69 with other health issues) took part. The goal was to see…
Phase: PHASE3 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New hope for kids with chronic graft-versus-host disease?
Disease control CompletedThis study tested the drug ibrutinib in children with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The goal was to find the best dose and check safety. Fifty-nine children aged 1 to 22 took part. The study is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC